乳腺癌类器官在临床及转化应用中的进展

doi:10.3760/cma.j.cn371439-20250110-00064

国际肿瘤学杂志 ›› 2025, Vol. 52 ›› Issue (6): 379-381.doi: 10.3760/cma.j.cn371439-20250110-00064

乳腺癌类器官在临床及转化应用中的进展

黎立喜¹, 段博识², 钱海利³, 马飞¹()

¹国家癌症中心国家肿瘤临床医学研究中心中国医学科学院北京协和医学院肿瘤医院内科，北京 100021
²国家癌症中心国家肿瘤临床医学研究中心中国医学科学院北京协和医学院肿瘤医院深圳医院肿瘤内科，深圳 518116
³国家癌症中心国家肿瘤临床医学研究中心中国医学科学院北京协和医学院分子肿瘤学国家重点实验室，北京 100021

收稿日期:2025-01-10 修回日期:2025-02-13 出版日期:2025-06-08 发布日期:2025-06-26
通讯作者: 马飞 E-mail:drmafei@126.com
基金资助:
国家重点研发计划(2024YFA1107400)

Advances in the clinical and translational applications of breast cancer organoids

Li Lixi¹, Duan Boshi², Qian Haili³, Ma Fei¹()

¹Department of Medical Oncology， National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital， Chinese Academy of Medical Sciences and Peking Union Medical College， Beijing 100021， China
²Department of Medical Oncology， National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital， Chinese Academy of Medical Sciences and Peking Union Medical College， Shenzhen 518116， China
³State Key Laboratory of Molecular Oncology， National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital， Chinese Academy of Medical Sciences and Peking Union Medical College， Beijing 100021， China

Received:2025-01-10 Revised:2025-02-13 Online:2025-06-08 Published:2025-06-26
Contact: Ma Fei E-mail:drmafei@126.com
Supported by:
National Key Research and Development Program of China(2024YFA1107400)

摘要/Abstract

摘要：

乳腺癌类器官在结构和功能上能够真实反映患者原始肿瘤特征，具有广泛的应用潜力。在临床应用中，类器官已被用于药物敏感性检测，显著提高个体化治疗方案的精准性，其在加速新药研发、揭示耐药机制及提升免疫疗效方面发挥重要作用。深入分析乳腺癌类器官技术在临床及转化中的应用，可为乳腺癌临床诊疗提供新的思路。

关键词: 乳腺肿瘤, 类器官, 药物评价，临床前, 精准医学

Abstract:

Breast cancer organoids faithfully reflect the structural and functional characteristics of primary tumors， demonstrating broad application potential. Clinically， organoids have been utilized for drug sensitivity testing， significantly enhancing the precision of personalized treatment strategies. Organoids play a crucial role in accelerating new drug development， uncovering drug resistance mechanisms， and improving the efficacy of immunotherapy. In-depth analysis of the application of breast cancer organoid technology in clinical and transformation can provide new ideas for clinical diagnosis and treatment of breast cancer.

Key words: Breast neoplasms, Organoids, Drug evaluation， preclinical, Precision medicine

黎立喜, 段博识, 钱海利, 马飞. 乳腺癌类器官在临床及转化应用中的进展[J]. 国际肿瘤学杂志, 2025, 52(6): 379-381.

Li Lixi, Duan Boshi, Qian Haili, Ma Fei. Advances in the clinical and translational applications of breast cancer organoids[J]. Journal of International Oncology, 2025, 52(6): 379-381.

参考文献 23

[1]	Tuveson D, Clevers H. Cancer modeling meets human organoid technology[J]. Science, 2019, 364(6444): 952-955. DOI: 10.1126/science.aaw6985. pmid: 31171691
[2]	Kopper O, de Witte CJ, Lõhmussaar K, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity[J]. Nat Med, 2019, 25(5): 838-849. DOI: 10.1038/s41591-019-0422-6. pmid: 31011202
[3]	Sachs N, de Ligt J, Kopper O, et al. A living biobank of breast cancer organoids captures disease heterogeneity[J]. Cell, 2018, 172(1/2): 373-386.e10. DOI: 10.1016/j.cell.2017.11.010.
[4]	Rosenbluth JM, Schackmann RCJ, Gray GK, et al. Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages[J]. Nat Commun, 2020, 11(1): 1711. DOI: 10.1038/s41467-020-15548-7.
[5]	Chen P, Zhang X, Ding R, et al. Patient-derived organoids can guide personalized-therapies for patients with advanced breast cancer[J]. Adv Sci (Weinh), 2021, 8(22): e2101176. DOI: 10.1002/advs.202101176.
[6]	Lin YY, Gao HF, Li H, et al. Clinical efficacy of tumor organoid-guided cancer therapy for locally advanced unresectable or metastatic breast cancer[J]. Int J Cancer, 2024, 155(4): 697-709. DOI: 10.1002/ijc.34945.
[7]	Shu D, Shen M, Li K, et al. Organoids from patient biopsy samples can predict the response of BC patients to neoadjuvant chemotherapy[J]. Ann Med, 2022, 54(1): 2581-2597. DOI: 10.1080/07853890.2022.2122550. pmid: 36194178
[8]	Ye HS, Zhou D, Li H, et al. Organoid forming potential as complementary parameter for accurate evaluation of breast cancer neoadjuvant therapeutic efficacy[J]. Br J Cancer, 2024, 130(7): 1109-1118. DOI: 10.1038/s41416-024-02595-w.
[9]	Beelen NA, Aberle MR, Bruno V, et al. Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids[J]. Front Immunol, 2023, 14: 1133796. DOI: 10.3389/fimmu.2023.1133796.
[10]	Jiang S, Deng T, Cheng H, et al. Macrophage-organoid co-culture model for identifying treatment strategies against macrophage-related gemcitabine resistance[J]. J Exp Clin Cancer Res, 2023, 42(1): 199. DOI: 10.1186/s13046-023-02756-4.
[11]	Ou L, Liu S, Wang H, et al. Patient-derived melanoma organoid models facilitate the assessment of immunotherapies[J]. EBioMedicine, 2023, 92: 104614. DOI: 10.1016/j.ebiom.2023.104614.
[12]	Xu NY, Li J, Wang ML, et al. Fabrication of a coculture organoid model in the biomimetic matrix of alginate to investigate breast cancer progression in a TAMs-leading immune microenvironment[J]. ACS Appl Mater Interfaces, 2024, 16(9): 11275-11288. DOI: 10.1021/acsami.3c17863.
[13]	Guillen KP, Fujita M, Butterfield AJ, et al. A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology[J]. Nat Cancer, 2022, 3(2): 232-250. DOI: 10.1038/s43018-022-00337-6.
[14]	Mao Y, Wang W, Yang J, et al. Drug repurposing screening and mechanism analysis based on human colorectal cancer organoids[J]. Protein Cell, 2024, 15(4): 285-304. DOI: 10.1093/procel/pwad038.
[15]	Chen B, Song Y, Zhan Y, et al. Fangchinoline inhibits non-small cell lung cancer metastasis by reversing epithelial-mesenchymal transition and suppressing the cytosolic ROS-related Akt-mTOR signaling pathway[J]. Cancer Lett, 2022, 543: 215783. DOI: 10.1016/j.canlet.2022.215783.
[16]	Ye HS, Gao HF, Li H, et al. Higher efficacy of resveratrol against advanced breast cancer organoids: a comparison with that of clinically relevant drugs[J]. Phytother Res, 2022, 36(8): 3313-3324. DOI: 10.1002/ptr.7515.
[17]	Mo H, Liu X, Xue Y, et al. S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer[J]. Mol Cancer, 2022, 21(1): 171. DOI: 10.1186/s12943-022-01642-5.
[18]	Arshad M, Azad A, Chan PYK, et al. Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models[J]. Br J Cancer, 2024, 130(12): 1990-2002. DOI: 10.1038/s41416-024-02665-z.
[19]	Duarte AA, Gogola E, Sachs N, et al. BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance[J]. Nat Methods, 2018, 15(2): 134-140. DOI: 10.1038/nmeth.4535. pmid: 29256493
[20]	Ding K, Chen F, Priedigkeit N, et al. Single cell heterogeneity and evolution of breast cancer bone metastasis and organoids reveals therapeutic targets for precision medicine[J]. Ann Oncol, 2022, 33(10): 1085-1088. DOI: 10.1016/j.annonc.2022.06.005. pmid: 35764274
[21]	Chew NJ, Lim Kam Sian TCC, Nguyen EV, et al. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models[J]. Breast Cancer Res, 2021, 23(1): 82. DOI: 10.1186/s13058-021-01461-4.
[22]	Michels BE, Mosa MH, Streibl BI, et al. Pooled in vitro and in vivo CRISPR-Cas9 screening identifies tumor suppressors in human colon organoids[J]. Cell Stem Cell, 2020, 26(5): 782-792.e7. DOI: 10.1016/j.stem.2020.04.003.
[23]	Lo YH, Kolahi KS, Du Y, et al. A CRISPR/Cas9-engineered ARID1A-deficient human gastric cancer organoid model reveals essential and nonessential modes of oncogenic transformation[J]. Cancer Discov, 2021, 11(6): 1562-1581. DOI: 10.1158/2159-8290.CD-20-1109.

乳腺癌类器官在临床及转化应用中的进展

Advances in the clinical and translational applications of breast cancer organoids

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 23

相关文章 15

编辑推荐

Metrics

本文评价

[1]	周文考, 黄何森, 潘艺梅, 黄灵炎, 王明山, 赵方俐, 王娅, 唐慧敏. 基于2型糖尿病的乳腺癌患者无复发生存预测模型构建与效能比较[J]. 国际肿瘤学杂志, 2025, 52(5): 295-303.
[2]	王智宝, 李广现, 张昕昕, 崔伟, 张微. MRI联合血清lncRNA KCNQ1OT1、miR-204-5p对乳腺癌腋窝淋巴结转移的预测价值[J]. 国际肿瘤学杂志, 2025, 52(2): 89-93.
[3]	韩晓旭, 张楠, 刘帅. 孕烷X受体在乳腺癌耐药中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(9): 590-594.
[4]	孟繁明. 伊尼妥单抗联合卡培他滨治疗曲妥珠单抗经治的HER2阳性晚期乳腺癌1例[J]. 国际肿瘤学杂志, 2024, 51(8): 538-541.
[5]	赵彪, 蒲琴, 袁美芳, 马立双, 李瀚, 杨毅, 孙朝细. 基于内缘切线野的调强放疗与容积弧形调强放疗在左侧乳腺癌保乳术后放疗中的剂量学研究[J]. 国际肿瘤学杂志, 2024, 51(7): 441-447.
[6]	刘琴, 张强强, 杨继元, 胡艳. 晚期前列腺癌双侧乳腺和腋窝淋巴结转移1例[J]. 国际肿瘤学杂志, 2024, 51(7): 478-480.
[7]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[8]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[9]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[10]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[11]	檀双秀, 张一丹, 王颖, 于鹏丽, 孔文韬, 姚静, 陈桥梁. 常规超声联合剪切波弹性成像鉴别非肿块型导管原位癌和浸润性乳腺癌的价值[J]. 国际肿瘤学杂志, 2024, 51(12): 743-748.
[12]	周名睿, 戚孟琪, 张妍妍, 史易暖, 岳川, 张妍, 刘宪强, 张岩. 人体组织中微生物群落与乳腺癌关系的研究进展[J]. 国际肿瘤学杂志, 2024, 51(12): 779-784.
[13]	朱彬, 万涛, 许华, 贾浩, 陈士新. 基于多模态MRI特征构建的预测模型用于BI-RADS 4类乳腺肿瘤良恶性鉴别诊断价值分析[J]. 国际肿瘤学杂志, 2024, 51(11): 678-683.
[14]	陶晋, 阚俊楠, 杨彩霞, 刘岩, 吕奕洁, 魏俊辉, 李祥林. 锰基纳米材料在乳腺癌诊疗中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(10): 645-649.
[15]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.